Literature DB >> 20184621

Psychosocial impact of Von Hippel-Lindau disease: levels and sources of distress.

C R M Lammens1, E M A Bleiker, S Verhoef, F J Hes, M G E M Ausems, D Majoor-Krakauer, R H Sijmons, R B van der Luijt, A M W van den Ouweland, T A M Van Os, N Hoogerbrugge, E B Gómez García, C J Dommering, C M Gundy, N K Aaronson.   

Abstract

Von Hippel-Lindau disease (VHL) is a hereditary tumor susceptibility syndrome, characterized by an increased risk of developing multiple benign and malignant tumors at various sites and ages with limited preventive options. This study evaluates the prevalence of distress among VHL family members and factors associated significantly with such distress. Forty-eight families with a VHL mutation were identified via the nine family cancer clinics in the Netherlands. In total, 171 family members (carriers, 50% at-risk, non-carriers) were approached, of whom 123 (72%) completed a self-report questionnaire. Approximately 40% of the VHL family members reported clinically relevant levels of distress, approaching 50% among the carriers and, possibly even more striking, 36% among the non-carriers. Having lost a first degree relative due to VHL during adolescence (OR 11.2; 95% CI 1.4-86.9) was related significantly to heightened levels of distress. Approximately, only one-third of those who reported heightened levels of distress had received professional psychosocial support. A substantial percentage of family members experience clinically relevant levels of distress. We would recommend the introduction of a procedure for screening for distress in this vulnerable population. Special attention should be paid to those individuals who have lost a close relative due to VHL during adolescence.

Entities:  

Mesh:

Year:  2010        PMID: 20184621     DOI: 10.1111/j.1399-0004.2010.01333.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

1.  Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes.

Authors:  Kelly L Stratton; Shaheen Alanee; Emily A Glogowski; Kasmintan A Schrader; Rohini Rau-Murthy; Robert Klein; Paul Russo; Jonathan Coleman; Kenneth Offit
Journal:  Urol Oncol       Date:  2015-12-23       Impact factor: 3.498

Review 2.  von Hippel-Lindau disease: a clinical and scientific review.

Authors:  Eamonn R Maher; Hartmut Ph Neumann; Stéphane Richard
Journal:  Eur J Hum Genet       Date:  2011-03-09       Impact factor: 4.246

3.  Disclosure of genetic risk to dating partners among young adults with von Hippel-Lindau disease.

Authors:  Elysa Bond; Beverly Yashar; Tobias Else; Jenae Osborne; Monica Marvin
Journal:  Fam Cancer       Date:  2022-08-19       Impact factor: 2.446

4.  A Novel von Hippel Lindau Gene Intronic Variant and Its Reclassification from VUS to Pathogenic: the Impact on a Large Family.

Authors:  A Sexton; L Rawlings; G McKavanagh; K Simons; I Winship
Journal:  J Genet Couns       Date:  2015-09-02       Impact factor: 2.537

5.  Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system.

Authors:  Claire Rochette; Karine Baumstarck; Hélène Canoni-Zattara; Ahmad Esmaeel Abdullah; Dominique Figarella-Branger; Morgane Pertuit; Anne Barlier; Frédéric Castinetti; Karel Pacak; Philippe Metellus; David Taïeb
Journal:  J Psychosoc Oncol       Date:  2018-05-15

6.  Through the looking glass: an exploratory study of the lived experiences and unmet needs of families affected by Von Hippel-Lindau disease.

Authors:  Nadine A Kasparian; Alison Rutstein; Ursula M Sansom-Daly; Shab Mireskandari; Janet Tyler; Jessica Duffy; Katherine M Tucker
Journal:  Eur J Hum Genet       Date:  2014-04-02       Impact factor: 4.246

7.  Multidisciplinary integrated care pathway for von Hippel-Lindau disease.

Authors:  Wendy P G Wolters; Koen M A Dreijerink; Rachel H Giles; Anouk N A van der Horst-Schrivers; Bernadette van Nesselrooij; Wouter T Zandee; Henri J L M Timmers; Tatjana Seute; Wouter W de Herder; Annemarie A Verrijn Stuart; Emine Kilic; Willem M Brinkman; Patricia J Zondervan; W Peter Vandertop; Anthony B Daniels; Tijmen Wolbers; Thera P Links; Rachel S van Leeuwaarde
Journal:  Cancer       Date:  2022-05-17       Impact factor: 6.921

8.  The efficacy of a standardized questionnaire in facilitating personalized communication about problems encountered in cancer genetic counseling: design of a randomized controlled trial.

Authors:  Willem Eijzenga; Neil K Aaronson; Irma Kluijt; Grace N Sidharta; Daniela Ee Hahn; Margreet Gem Ausems; Eveline Ma Bleiker
Journal:  BMC Cancer       Date:  2014-01-15       Impact factor: 4.430

9.  Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance.

Authors:  Ingrid C A W Konings; Femme Harinck; Marianne A Kuenen; Grace N Sidharta; Jacobien M Kieffer; Cora M Aalfs; Jan-Werner Poley; Ellen M A Smets; Anja Wagner; Anja van Rens; Frank P Vleggaar; Margreet G E M Ausems; Paul Fockens; Jeanin E van Hooft; Marco J Bruno; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.